Literature DB >> 23085343

Leukemia specific loss of heterozygosity of MHC in a CLL patient: disease state impacts timing of confirmatory typing.

Myra Coppage1, Anwar Iqbal, Ausaf Ahmad, Michael W Becker.   

Abstract

A 63 year old white male with refractory B-CLL presented for allogeneic HSCT evaluation; HLA typing was performed on PBL at time of WBC = 53K, ALC = 47K and revealed homozygosity at Class I locus and heterozygosity at Class II locus. Two siblings were full mismatches with the recipient and an unrelated search initiated. The patient was treated with Fludaribine and Rituxan complicated by aplastic anemia and bacteremia. Prior to transplant, confirmatory typing performed on PB revealed two full haplotypes at Class I and II. Sample identification error and the presence of third party lymphocyte engraftment as a result of prior red cell or granulocyte transfusion(s) were ruled out by STR analysis of 8 loci of all samples, T and B cells from cryopreserved PB at blast crisis were HLA typed independently. T cell typing yielded both complete haplotypes (genotype verified by offspring HLA typing); B cells typed for homozygous haplotype indicating loss of heterozygosity of MHC locus. Microarray based comparative genomic hybridization of tumor cells confirmed LOH at 6p.
Copyright © 2012 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23085343     DOI: 10.1016/j.humimm.2012.10.003

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  4 in total

1.  Erroneous HLA typing as a result of acquired uniparental disomy in a patient with acute lymphoblastic leukaemia in peripheral blood complete remission.

Authors:  Andrea Bontadini; Sandra Iannelli; Fiorenza Fruet; Simonetta Capelli; Riccardo Masetti; Valérie Dubois; Jean-Marie Tiercy; Arcangelo Prete
Journal:  Blood Transfus       Date:  2015-01-29       Impact factor: 3.443

2.  Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation.

Authors:  L Crucitti; R Crocchiolo; C Toffalori; B Mazzi; R Greco; A Signori; F Sizzano; L Chiesa; E Zino; M T Lupo Stanghellini; A Assanelli; M G Carrabba; S Marktel; M Marcatti; C Bordignon; C Corti; M Bernardi; J Peccatori; C Bonini; K Fleischhauer; F Ciceri; L Vago
Journal:  Leukemia       Date:  2014-11-05       Impact factor: 11.528

3.  Combination of Complement-Dependent Cytotoxicity and Relative Fluorescent Quantification of HLA Length Polymorphisms Facilitates the Detection of a Loss of Heterozygosity.

Authors:  Klaus Witter; Roland Reibke; Marion Subklewe; Robert Zahn; Teresa Kauke; Karsten Spiekermann; Michael Spannagl; Johanna Tischer; Wolfgang Hiddemann; Andrea Dick
Journal:  Bone Marrow Res       Date:  2014-04-03

4.  An Integrated Genomic, Proteomic, and Immunopeptidomic Approach to Discover Treatment-Induced Neoantigens.

Authors:  Niclas Olsson; Marlene L Heberling; Lichao Zhang; Suchit Jhunjhunwala; Qui T Phung; Sarah Lin; Veronica G Anania; Jennie R Lill; Joshua E Elias
Journal:  Front Immunol       Date:  2021-04-15       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.